Literature DB >> 12150485

Levels of interferon-gamma and interleukin-2 receptor-alpha for bronchoalveolar lavage fluid and serum were correlated with clinical grade and treatment of pulmonary tuberculosis.

T C Y Tsao1, C C Huang, W K Chiou, P Y Yang, M J Hsieh, K C Tsao.   

Abstract

OBJECTIVE: We investigated possible correlations for interferon-gamma (IFN-gamma) and soluble interleukin-2 receptor-alpha (sIL-2R-alpha) levels in bronchoalveolar lavage fluid (BALF), and clinical grade of pulmonary tuberculosis (TB), which is determined by factors such as extent of pulmonary involvement, fever and loss of body weight.
DESIGN: In order to explore these correlations and address associated questions, BALF was collected from 45 patients presenting with active pulmonary TB and 14 healthy controls. Repetitive BALF was collected in 17 patients after 3 months of anti-tuberculosis chemotherapy. The epithelial lining fluid (ELF) levels for IFN-gamma and sIL-2R-alpha were measured using enzyme-linked immunosorbent assay (ELISA) after standardization with urea.
RESULTS: Patients with higher-grade pulmonary TB (i.e., with more advanced pulmonary involvement, fever or body weight loss), revealed significantly higher ELF levels for IFN-gamma and sIL-2R-alpha compared to those with lower grade pulmonary TB. Similar results were also determined for sIL-2R-alpha serum levels, but not for IFN-gamma serum levels. After anti-tuberculosis chemotherapy the elevated cytokine levels for ELF and serum significantly decreased in accordance with radiographic improvement.
CONCLUSIONS: ELF levels of IFN-gamma and sIL-2R-alpha were correlated with disease grading of pulmonary TB and decreased after anti-tuberculosis chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12150485

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  22 in total

Review 1.  Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection.

Authors:  Katrin D Mayer-Barber; Daniel L Barber
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-17       Impact factor: 6.915

2.  Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis.

Authors:  A Jayakumar; E Vittinghoff; M R Segal; W R MacKenzie; J L Johnson; P Gitta; J Saukkonen; J Anderson; M Weiner; M Engle; C Yoon; M Kato-Maeda; P Nahid
Journal:  Tuberculosis (Edinb)       Date:  2015-05-09       Impact factor: 3.131

3.  Molecular characterization of clinical isolates of Mycobacterium tuberculosis and their association with phenotypic virulence in human macrophages.

Authors:  K C Wong; W M Leong; H K W Law; K F Ip; J T H Lam; K Y Yuen; P L Ho; W S Tse; X H Weng; W H Zhang; S Chen; W C Yam
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

4.  In-hospital mortality of disseminated tuberculosis in patients infected with the human immunodeficiency virus.

Authors:  Rodrigo Pires dos Santos; Caroline Deutschendorf; Karin Scheid; Luciano Zubaran Goldani
Journal:  Clin Dev Immunol       Date:  2010-08-04

Review 5.  Defining features of protective CD4 T cell responses to Mycobacterium tuberculosis.

Authors:  Shunsuke Sakai; Katrin D Mayer-Barber; Daniel L Barber
Journal:  Curr Opin Immunol       Date:  2014-08       Impact factor: 7.486

Review 6.  [Immune response to Mycobacterium tuberculosis].

Authors:  A Nowag; P Hartmann
Journal:  Internist (Berl)       Date:  2016-02       Impact factor: 0.743

7.  Plasma Proinflammatory Cytokines Are Markers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis.

Authors:  Nathella Pavan Kumar; Kadar Moideen; Vaithilingam V Banurekha; Dina Nair; Subash Babu
Journal:  Open Forum Infect Dis       Date:  2019-05-31       Impact factor: 3.835

8.  Increased cytokines response in patients with tuberculosis complicated with chronic obstructive pulmonary disease.

Authors:  Shenjie Tang; Haiyan Cui; Lan Yao; Xiaohui Hao; Yun Shen; Lin Fan; Hua Sun; Zhanjun Zhang; Jian An Huang
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

9.  Enhancement of CD4+ T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work?

Authors:  Diego L Costa; Eduardo P Amaral; Sivaranjani Namasivayam; Lara R Mittereder; Bruno B Andrade; Alan Sher
Journal:  Front Cell Infect Microbiol       Date:  2021-06-21       Impact factor: 5.293

10.  Immune responses in the lungs of patients with tuberculous pleural effusion without pulmonary tuberculosis.

Authors:  Diana Qama; Won-Il Choi; Kun Young Kwon
Journal:  BMC Immunol       Date:  2012-08-13       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.